FDA declines to approve Bristol-Myers hepatitis drug

November 26, 2014 6:06 PM

3 0

(Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.

Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York-based company's experimental medicines.

Also read: Cyber Monday sales spike 9.4 percent, early data shows

Read more

To category page

Loading...